Utilisation of angiotensin receptor blockers in Sweden: Combining survey and register data to study adherence to prescribing guidelines

European Journal of Clinical Pharmacology

Volumn 64, Issue 12, 2008, Pages 1223-1229

  Frisk, Pia ^a   Mellgren, Tor Olov ^b   Hedberg, Niklas ^b   Berlin, Anita ^a   Granath, Fredrik ^c   Wettermark, Björn ^c  

^a Apoteket AB   (Sweden)

^b Swedish Pharmaceutical Benefits Board (LFN)   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Drug utilisation; Guidelines; Patient survey; Prescribing

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; VALSARTAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; SEX RATIO; SWEDEN; TREATMENT INDICATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PRESCRIPTION DRUGS; QUESTIONNAIRES; RECEPTORS, ANGIOTENSIN; REGISTRIES; SWEDEN;

EID: 57049108131     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0495-5     Document Type: Article

References (36)

1. Kaplan W, Laing R (2004) Priority Medicines for Europe and the World Project. A Public Health Approach to Innovation. WHO, Geneva. Retrieved on 2008.07.21 from http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf.
2. J Leal R Luengo-Fernandez A Gray S Petersen M Rayner 2006 Economic burden of cardiovascular diseases in the enlarged European Union Eur Heart J 27 1610 1619
3. G Mancia 2007 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 1462 536
4. JA Staessen Y Li L Thijs JG Wang 2005 Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials Hypertens Res 28 385 407
5. K Swedberg J Cleland H Dargie H Drexler F Follath M Komajda 2005 Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 1115 1140
6. DB Matchar DC McCrory LA Orlando MR Patel UD Patel MB Patwardhan 2008 Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension Ann Intern Med 148 16 29
7. B Dahlöf RB Devereux SE Kjeldsen S Julius G Beevers U de Faire 2002 Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995 1003
8. S Julius SE Kjeldsen M Weber HR Brunner S Ekman L Hansson 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022 2031
9. H Lithell L Hansson I Skoog D Elmfeldt A Hofman B Olofsson 2003 The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 875 886
10. Swedish Council on Technology Assessment in Health Care (SBU) (2004) Moderately Elevated Blood Pressure. SBU report 170. Stockholm. Retrieved on 2008.04.18 from http://www.sbu.se/en/Published/Yellow/Moderately-Elevated-Blood- Pressure/
11. CB Granger JJ McMurray S Yusuf P Held EL Michelson B Olofsson 2003 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 772 776
12. MA Pfeffer JJ McMurray EJ Velazquez JL Rouleau L Kober AP Maggioni 2003 Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 20 1893 1906
13. MA Pfeffer K Swedberg CB Granger P Held JJ McMurray EL Michelson 2003 Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 759 766
14. Fletcher AE, Palmer AJ, Bulpitt CJ (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens Suppl 12:S43-S47
15. Pharmaceutical Benefits Board price database, http://www.lfn.se
16. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2560 2572
17. SA Hunt WT Abraham MH Chin AM Feldman GS Francis TG Ganiats 2005 ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Circulation 112 e154 e235
18. JP Greving P Denig WJ van der Veen FW Beltman MC Sturkenboom D de Zeeuw 2004 Does comorbidity explain trends in prescribing of newer antihypertensive agents? J Hypertens 22 2209 2215
19. CA Jackevicius K Tu WA Filate SE Brien JV Tu 2003 Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001 Can J Cardiol 19 1359 1366
20. T Walley AK Duggan AR Haycox CJ Niziol 2003 Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK J R Soc Med 96 525 531
21. B Wettermark N Hammar C MichaelFored A Leimanis P Otterblad Olausson U Bergman 2007 The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months Pharmacoepidemiol Drug Saf 16 726 735
22. World Health Organization (WHO) (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology, Oslo, www.whocc.no
23. World Health Organization (WHO) (2003) Introduction to Drug Utilisation Research, NLM classification WB 330, Oslo
24. S Hallas 2006 Templates for Analysis of Individual-Level Prescription Data Basic Clin Pharmacol Toxicol 98 260 265
25. HI Feldman BL Strom 1991 Utilisation of drugs for diabetes mellitus Drug Saf 6 220 229
26. Strom B (2005) Pharmacoepidemiology, 4th edn. John Wiley and Sons, Chichester
27. R Charlton 2000 Research: is an 'ideal' questionnaire possible? Int J Clin Pract 54 356 359
28. J Jesson 2001 Cross-sectional studies in prescribing research J Clin Pharm Ther 26 397 403
29. B Sibbald JM Addington-Hall D Brenneman P Freeling 1994 Telephone versus postal surveys of general practitioners: methodological considerations Br J Gen Pract 44 297 300
30. BS Bloom 1998 Continuation of initial antihypertensive medication after 1 year of therapy Clin Ther 20 671 681
31. E Degli Esposti A Sturani M Di Martino P Falasca MV Novi G Baio 2002 Long-term persistence with antihypertensive drugs in new patients J Human Hypertens 16 439 444
32. JP Greving P Denig WJ van der Veen FW Beltman MC Sturkenboom D de Zeeuw 2005 Uptake of angiotensin II receptor blockers in the treatment of hypertension Eur J Clin Pharmacol 61 461 466
33. S Perreault D Lamarre L Blais A Dragomir D Berbiche 2005 Persistence with treatment in newly treated middle-aged patients with essential hypertension Ann Pharmacother 39 1401 1408
34. E Poluzzi P Strahinja A Vargiu G Chiabrando MC Silvani 2005 Initial treatment of hypertension and adherence to therapy in general practice in Italy Eur J Clin Pharmacol 61 603 609
35. JP Greving P Denig WJ van der Veen FW Beltman MC Sturkenboom FM Haaijer-Ruskamp 2006 Determinants for the adoption of angiotensin II receptor blockers by general practitioners Soc Sci Med 63 2890 2898
36. Swedish Pharmaceutical Benefits Board (LFN) (2008) Summary: A review of medicines for lowering blood pressure. Stockholm. Retrieved on 2008.04.18 from http://www.lfn.se/LFNTemplates/Page____1779.aspx